Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

NCT03894007 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Security and effect data from another ongoing study.

Conditions

Early-stage Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Atezolizumab
DRUG: Trastuzumab emtansine
DRUG: Paclitaxel

Sponsor

Renske Altena